BOUL Stock Overview
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Boule Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr10.00 |
| 52 Week High | kr12.62 |
| 52 Week Low | kr8.66 |
| Beta | 0.52 |
| 1 Month Change | 5.49% |
| 3 Month Change | -3.10% |
| 1 Year Change | -11.50% |
| 3 Year Change | -84.00% |
| 5 Year Change | -82.88% |
| Change since IPO | -14.71% |
Recent News & Updates
Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates
May 10
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Mar 20Recent updates
Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates
May 10Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Mar 20Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results
Feb 09Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch
Dec 30Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Jul 25Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 26Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals
Jul 26Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)
Jul 19We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt
Mar 06Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Feb 03The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing
Apr 29Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?
Apr 09Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Mar 25Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend
Mar 07Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?
Feb 17
These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively
Jan 30Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?
Jan 14How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?
Dec 28Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Dec 10What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?
Nov 22Shareholder Returns
| BOUL | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 2.8% |
| 1Y | -11.5% | -5.1% | 13.6% |
Return vs Industry: BOUL underperformed the Swedish Medical Equipment industry which returned -5.1% over the past year.
Return vs Market: BOUL underperformed the Swedish Market which returned 13.6% over the past year.
Price Volatility
| BOUL volatility | |
|---|---|
| BOUL Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: BOUL has not had significant price volatility in the past 3 months.
Volatility Over Time: BOUL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 228 | Torben Nielsen | www.boule.com |
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics companies.
Boule Diagnostics AB (publ) Fundamentals Summary
| BOUL fundamental statistics | |
|---|---|
| Market cap | kr388.33m |
| Earnings (TTM) | kr26.88m |
| Revenue (TTM) | kr576.03m |
14.4x
P/E Ratio0.7x
P/S RatioIs BOUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOUL income statement (TTM) | |
|---|---|
| Revenue | kr576.03m |
| Cost of Revenue | kr324.02m |
| Gross Profit | kr252.01m |
| Other Expenses | kr225.14m |
| Earnings | kr26.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 22, 2024
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 43.75% |
| Net Profit Margin | 4.67% |
| Debt/Equity Ratio | 31.5% |
How did BOUL perform over the long term?
See historical performance and comparison